cAMP-specific 3',5'-cyclic phosphodiesterase 4A (PDE4A)

Phosphodiesterase-4A (PDE4A) is a member of the PDE4 family of enzymes that specifically hydrolyzes the second messenger cyclic adenosine monophosphate (cAMP) into 5'-AMP (UniProt P27815). It is widely expressed in the central nervous system, immune cells (including T cells, monocytes, and neutrophils), and cardiovascular tissues (PMC11165135, PMC6617413). By regulating intracellular cAMP levels, PDE4A modulates key signaling pathways involving protein kinase A (PKA) and Epac, which are essential for controlling inflammatory mediator production and maintaining epithelial integrity (PMC6617413, Patsnap). Dysregulation of PDE4A is implicated in the pathogenesis of chronic inflammatory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and psoriasis, as well as neurodegenerative conditions like Parkinson's disease (Neurology 2017, PMC11165135). Therapeutic targeting of PDE4A with inhibitors like roflumilast and apremilast aims to elevate cAMP levels to suppress pro-inflammatory cytokines (e.g., TNF-alpha, IL-17) and promote anti-inflammatory responses (PMC6617413, Patsnap). However, the clinical utility of systemic PDE4 inhibitors is often limited by side effects such as nausea, vomiting, and weight loss, prompting the development of more selective or tissue-targeted delivery methods (PMC6617413, PMC6702618). PDE4A also plays a role in regulating vascular smooth muscle proliferation and endothelial permeability, making it a potential target for cardiovascular therapies (PMC11165135).

Other names

PDE4DPDE2PDE46cAMP-specific phosphodiesterase 4A

Inhibition of cAMP hydrolysis, leading to increased intracellular cAMP levels and suppression of inflammatory mediators.